Search Results

standard regimen. As shown in Figure 2 , RDI less than 85% ranged from 15.6% for patients with breast cancer treated with dose-dense AC followed by paclitaxel every 2 weeks to 87.6% for patients with CRC treated with 5-FU (every 8 weeks). Colony

constitute what most observers would consider appropriate use. The 10 drugs in this analysis (albumin-bound paclitaxel, azacytidine, bevacizumab, bortezomib, cetuximab, docetaxel, gemcitabine, pemetrexed, rituximab, and trastuzumab) are products well

additional research into reducing readmissions after surgery for ovarian cancer. 26 An interesting finding was the decrease in outpatient costs after 2005. This may reflect the availability of generic versions of paclitaxel in 2002, 27 carboplatin in 2004

paclitaxel, cisplatin, plus gemcitabine (PCG) triplet are also effective treatments based on median survivals of 14 and 16 months, respectively. 7 , 8 Dose-dense MVAC plus G-CSF, the GC doublet, and the PCG triplet are NCCN Clinical Practice Guidelines in

, chemotherapy should include cisplatin, cisplatin/vinorelbine, or cisplatin/paclitaxel. “The site of the cancer matters,” said Wui-Jin Koh, MD, Professor at Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance and Co-Chair of the NCCN Vulvar

. 26. Burstein HJ Bellon JR Galper S . Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for stage II or III breast cancer . Int J Radiat Oncol Biol Phys 2006 ; 64

lymphedema despite chemotherapy with pegylated liposomal doxorubicin (PLD; 20 mg/m 2 intravenously every 3 weeks) and paclitaxel (80 mg/m 2 intravenously every 3 weeks). Figure 1. (A) Cutaneous CKS (hematoxylin-eosin, original magnification ×40). (B

microtubules in mouse fibroblast cells . Proc Natl Acad Sci USA 1980 ; 77 : 1561 – 1565 . 16 Monzo M Rosell R Sanchez JJ . Paclitaxel resistance in non-small-cell lung cancer associated with beta-tubulin gene mutations . J Clin Oncol 1999 ; 17

paclitaxel/carboplatin either alone or in addition to trastuzumab weekly for 7 doses before surgery and, beginning 21 to 56 days after esophagectomy, every 3 weeks for 13 cycles in the absence of disease progression or unacceptable toxicity. In the metastatic

mortality (hazard ratio, 1.40; 95% CI, 1.13–1.74). 5 However, this category did not include patients who received paclitaxel with bevacizumab, because this combination was included in the NCCN Guidelines during our study period based on its accelerated